CGON (CG Oncology) Short-Term Debt : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Short-Term Debt?

CG Oncology's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

CG Oncology's annual Short-Term Debt declined from Dec. 2022 ($8.97 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

CG Oncology Short-Term Debt Historical Data

The historical data trend for CG Oncology's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Short-Term Debt Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

2.94

8.97

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial					-	-	-	-	-

CG Oncology Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CG Oncology Short-Term Debt Related Terms

Thank you for viewing the detailed overview of CG Oncology's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.